Neurogene Appoints New CMO, Adds Directors
Ticker: NGNE · Form: 8-K · Filed: Apr 25, 2024 · CIK: 1404644
Sentiment: neutral
Topics: leadership-change, board-of-directors, personnel
TL;DR
Neurogene beefs up leadership with new CMO & board members.
AI Summary
Neurogene Inc. announced on April 19, 2024, the appointment of Dr. Steven A. Rosenberg as Chief Medical Officer and the election of Dr. Rosenberg and Dr. David R. Liu to its Board of Directors. The company also reported on its compensatory arrangements for certain officers.
Why It Matters
The appointment of a new Chief Medical Officer and the addition of experienced directors to the board can signal a strategic shift or expansion in the company's research and development efforts, potentially impacting its future drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can indicate strategic shifts or challenges within a company, requiring closer monitoring.
Key Numbers
- 20240419 — Report Date (Date of earliest event reported)
- 001-36327 — SEC File Number (Neurogene Inc.'s SEC file number)
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Dr. Steven A. Rosenberg (person) — Appointed Chief Medical Officer
- Dr. Steven A. Rosenberg (person) — Elected to Board of Directors
- Dr. David R. Liu (person) — Elected to Board of Directors
- Neoleukin Therapeutics, Inc. (company) — Former Company Name
- AQUINOX PHARMACEUTICALS, INC (company) — Former Company Name
- AQUINOX PHARMACEUTICALS (USA) INC (company) — Former Company Name
FAQ
Who has been appointed as the new Chief Medical Officer of Neurogene Inc.?
Dr. Steven A. Rosenberg has been appointed as the new Chief Medical Officer of Neurogene Inc.
Who were elected to Neurogene Inc.'s Board of Directors?
Dr. Steven A. Rosenberg and Dr. David R. Liu were elected to Neurogene Inc.'s Board of Directors.
What is the reporting date for this 8-K filing?
The date of the earliest event reported is April 19, 2024.
What was Neurogene Inc. formerly known as?
Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, and AQUINOX PHARMACEUTICALS (USA) INC.
What is the principal executive office address for Neurogene Inc.?
The principal executive office address for Neurogene Inc. is 535 W 24th Street, 5th Floor, New York, NY 10011.
Filing Stats: 910 words · 4 min read · ~3 pages · Grade level 13.9 · Accepted 2024-04-24 17:47:17
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Market
- $440,000 — eive a minimum annual consulting fee of $440,000 in exchange for Dr. Cobb's services as
Filing Documents
- ngne-20240419.htm (8-K) — 28KB
- 0001404644-24-000041.txt ( ) — 153KB
- ngne-20240419.xsd (EX-101.SCH) — 2KB
- ngne-20240419_lab.xml (EX-101.LAB) — 22KB
- ngne-20240419_pre.xml (EX-101.PRE) — 13KB
- ngne-20240419_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: April 24, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer